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Alpha-1 antitrypsin (AAT) deficiency is an inherited disorder that causes low levels of, or no AAT in the 
blood. The most common illness in adults with AAT deficiency is lung disease during the third and 
fourth decades of life. Most commonly, it is associated with chronic obstructive pulmonary disease 
(COPD). Mutations in the protease inhibitor (PI) gene, located on chromosome 14, are associated with 
this genetic disorder. The Z protein is due to a single amino acid substitution of 342 glutamine lysine. 
Although cigarette smoking is the main environmental risk factor, only about 15% of smokers develop 
clinically significant disease suggesting other influences on disease expression. The study included 
hospital based age and sex matched 100 cases of COPD and 100 controls without COPD recruited from 
Christian Medical Centre, Jorhat, Assam. These cases were recruited from February 2009 to December 
2009. Subjects were included in the COPD group on the basis of lung function test. DNA extraction was 
done by DNA extraction kit and amplification for AAT gene was done by site directed mutagenesis 
polymerase chain reaction (PCR) method as described by Tazellar et al. (1992). We found that smoking 
was the prior cause of COPD. A1AT deficiency is not prevalent in our population subset but certain 
other genes could be the attributable factor for COPD.  
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INTRODUCTION 
 
One of the most significant breakthroughs in the field of 
chronic obstructive pulmonary disease (COPD), in the 
past 30 years was the discovery of a close association 
between an inherited deficiency of a protein in the blood 
called the Alpha-1- antitrypsin (AAT). It is the only known 
genetic   disorder  that  leads  to  COPD.  AAT  deficiency 
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Abbreviations: AAT or A1AT, Alpha-1-antitrypsin; COPD, 
chronic obstructive pulmonary disease; FEV1, forced expiratory 
volume in one second; FVC, forced vital capacity. 
accounts for less than one percent of COPD in USA 
(ATS, 1995). This deficiency is an autosomal hereditary 
disorder in which there is low level of AAT in serum and 
lung, with a high risk of development of panlobular 
emphysema in the third to fifth decade. The enzyme is 
synthesized and secreted by the hepatocytes and to a 
lesser extent by the mononuclear phagocytes, and then 
is released in to the blood from which it then diffuses in to 
the lungs (Crystal et al., 1990). AAT is a glycoprotein 
coded for by a single gene on chromosome 14; it is a 
serine protease inhibitor with primary function of 
inhabiting neutrophil elastase. Emphysema results from 
an imbalance between the neutrophil elastase in the lung 
and the anti-elastase. While the former has the capability 
of destroying  elastin  and  other  tissue  components, the 
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later is responsible for protecting the lung from elastase.  
This concept is known as the “elastase –anti elastase 
balance hypothesis of emphysema.”  The concept has 
been proved both in humans and animal experiments. 
According to the theory, either an excess of protease or a 
deficiency in the amount of functional activity of anti-
protease or both can lead to the development of 
emphysema. 
At least 75 alleles of the AAT gene have been identified 
(Guidelines for the approach to the patient with severe 
hereditary AAT deficiency, 1995) and categorized in to 
the protease inhibitor (PI) system.  
The normal and deficient AAT alleles are designed 
from A to Z on the basis of their electrophoretic mobility. 
The families of normal AAT alleles are referred to as M 
(M1, M2, and M3) and are found in approximately 90% of 
the population. The most deficient allele associated with 
emphysema is the Z allele .The AAT phenotype, there-
fore, is made up of the two parental alleles and is referred 
to as Pi phenotype. AAT variants are inherited as co-
dominant alleles. The most common phenotype is PiMM 
(PiM2M3) and the most common deficient phenotype 
associated with a high risk for the disease is PiZZ. The 
specific mutations responsible for many forms of AAT 
deficiency have been identified. The abnormal Z allele is 
associated with replacement of glutamic acid by lysine at 
position 342 as a result of a single base mutation from 
GAG to AAG. This substitution results in alteration of the 
three dimensional configuration of the molecule, thus it 
aggregates in the rough endoplasmic reticulum of the 
hepatocyte and consequently a decreased secretion of 
AAT occurs from the liver to about 15% of the normal 
(Weinberger et al., 1993; Crystal et al., 1990). 
Epidemiological studies indicate that a threshold value 
of 11αM or about 35% of the average normal level is 
sufficient to protect the lungs. It follows therefore, that 
individuals who are at greater risk are PiZZ homozygotes, 
the null homozygotes, and, occasionally PiSZ hetero-
zygotes. Severe AAT deficiency lead to premature 
emphysema of the panacinar type with more severe 
affection at the bases, and is often associated with 
chronic bronchitis and occasionally with bronchiectasis 
(Snider et al., 1989). Individuals with a PiZZ phenotype 
who smoke cigarettes are at increased risk, therefore 
becoming symptomatic earlier with dyspnea occurring at 
a median age of about 40 years. Smokers with AAT 
deficiency and COPD will have a life expectancy that is 
approximately 10 years less than the nonsmokers with 
this condition. Severity of lung disease varies 
considerably. Patients, who are detected on population 
surveys, only live longer to the age of 80 or 90 years. 
Airflow obstruction occurs more in men. Other risk factors 
are asthma, recurrent respiratory infections and familial 
factors (Silverman et al., 1989).                        
Many Indian studies have tried to examine the role of 
AAT deficiency in the causation of COPD and is sum-
marized by Malik et  al.  (1977).  The  heterozygote  state 
 
 
 
 
(intermediate) was found to be 10.3 to 23.3% and 
homozygous (severe) state in 2.8 to 20% of cases of 
COPD. The present study was undertaken at Jorhat, 
Assam, to screen the A1AT gene for carriers of ZZ allele, 
in individuals with COPD against controls. 
  
 
Study design  
 
The study included hospital based age and sex matched, 
a 100 cases of COPD and 100 controls without COPD 
recruited from Christian Medical Centre, Jorhat , Assam. 
These cases were recruited from February 2009 to 
December 2009. Data was abstracted from the medical 
records of participants regarding the diagnosis of COPD 
based on pre and post bronchodialator spirometry, radio-
logical examination, history of smoking and occupational 
exposure. Informed consent was taken from all the 
individuals participating in the study. The study was 
carried out at CSIR (NEIST), Jorhat after ethical clea-
rance from Institutional Ethics Committee NEIST, Jorhat.  
 
 
MATERIALS AND METHODS 
 
Diagnosis and inclusion criteria of subjects 
 
Altogether, 200 individuals (134 males and 66 females) were 
enrolled in our study. Spirometry was conducted with Spirometer 
(Model Schiller, USA) for each subject and the data for forced vital 
capacity (FVC) and forced expiratory volume in one second/forced 
vital capacity (FEV1/FVC) were recorded. Inclusion criteria 
comprises of the following symptoms: chronic airway symptoms and 
signs such as coughing, breathlessness, wheezing and chronic 
airway obstruction defined as FEV1/FVC of 70% and below, and an 
FVC of 80% of the predicted value. At the baseline, pre-
bronchodialator spirometry was done for all the subjects. Then we 
tested for bronchodialator reversibility where each individual was 
first administered with four puffs of Metered dose inhaler (100 
µg/puff) of Salbutamol. They were allowed to rest for 15 mins and 
post-bronchodialator spirometry was performed. Irreversible airflow 
limitation was confirmed when FEV1 was less than 12%. These 
persons were included in symptomatic COPD group. Prior to 
spirometry, we performed radiological examinations of these 
patients to rule out the existence of any structural lung disease. The 
criteria for selection of asymptomatic (Non-COPD) subjects were on 
the basis of non-existence of respiratory symptoms. The spirometry 
of these subjects was above 80% of the predicted value. Based on 
survey data and lung function analysis, the subjects were sorted as: 
 
 (a) Non-COPD (Smokers, n = 62 and non-smokers, n = 38) 
 (b) COPD (Smokers, n = 78 and non-smokers, n = 22). 
 
 
Blood sample collection 
 
An amount of 3 cc of whole blood was drawn from each individual 
by venipuncture and stored in ethylene diamine tetra-acetic acid 
(EDTA) vials. The vials were stored at 4°C until DNA extraction. 
 
 
DNA extraction and PCR amplification 
 
Genomic   DNA  was  extracted  from  whole  blood  using  GeNeiTM  
  
 
 
whole blood DNA extraction kit, Bangalore Genei, India. PCR 
amplification for carriers of ZZ allele for AAT gene was done by site 
directed mutagenesis PCR method as described by Tazellar et al. 
(1992) with slight modifications. Subsequently, restriction digestion 
was done to distinguish the normal MM allele from the mutant ZZ 
allele. 
 
Forward primer: ATAAGGCTGTGCTGACCATCGTC 
Reverse primer: CTTTTCACCACTTAGGGTGGGTT 
 
All amplifications were started in a 50 µl reaction volume containing 
25 µM deoxynucleotide  triphosphate [dNTP  (Bangalore GeNei, 
India)], 2 mM magnesium chloride (MgCl2))  (Bangalore GeNei, 
India), 20 pM of each primer synthesized by Sigma Aldrich (USA), 
200 ng DNA, 2.5 U Taq polymerase (Sigma Aldrich , USA). An 
initial denaturation was carried out at 94°C for 10 min, amplification 
was carried out for 30 cycles, each cycle consisted of 2 min 
denaturation time at 94°C, 2 min annealing time at 52°C and 3 min 
extension time, at 64°C followed by  a final extension of 10 min at 
72°C.The PCR reaction was done in a thermal cycler (Applied 
Biosystems, USA, model 2720). 
 
 
Restriction enzyme digestion and electrophoresis 
 
10 µl of all the PCR products were then digested with Taq I (50 U) 
restriction enzyme (Sigma Aldrich, USA) diluted with 1x 
endonuclease buffer (Sigma Aldrich, USA) and volume made up to 
20 µl. This digestion mixture was incubated at 65ºC for 2 h 
according to manufacturer’s instructions. Finally, the digested 
products were analysed in a 3% agarose gel (Amresco Superfine 
Resolution Grade, USA) in 89 mM Tris-borate buffer containing 1 
mM EDTA, pH 8.3 at constant 120 V for 1 h. 
 
 
Sequencing of AAT gene 
 
The PCR products, one each from COPD smoker, non-COPD 
smoker, non-COPD non-smoker and COPD non-smoker, were 
sequenced at Vimta labs, Hyderabad, India. The DNA sequencing 
samples were processed using ABI 3130 (4 capillary) or 3730 Xl 
(96 capillary) electrophoresis instruments.  We have used EMBOSS 
needle (global) pairwise sequence alignment algorithm to find the 
mutation if any at the position Glu 342 GAG Lys     AAG of the 
sequence. 
 
 
Statistical analyses 
 
Statistical analysis was carried out using chi-square test for 
categorical variables and students t-test for continuous variables. 
Data were tabulated and classified as per the age, sex, smoking 
and lung function status. Chi-square test with Yates correction was 
applied to test significant difference in the number between smoker 
and non-smokers, males and females amongst COPD and non-
COPD subjects. Unpaired t-test was applied to test for significant 
difference in smoking (pack-years), age, and lung function amongst 
the COPD and non-COPD subjects. 
 
 
RESULTS 
 
Demographic observations 
 
Detailed   observations   in    demographic   variables  are 
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shown in Table 1.The occurrence of COPD was 
significantly higher in male smokers [X2 = 2.87, p = 0.09, 
OR = 1.84 (0.8 - 3.96)] than female smokers [X2 = 0.12, p 
= 0.72, OR = 1.23 (0.34 - 4.61)]. There was no significant 
difference of age in the occurrence of COPD in smokers 
and non-smokers compared to non-COPD smokers and 
non-smokers. The lung function status was significantly 
different amongst COPDs and non-COPDs in both 
smoker [t = 18.37, df = 138, p = 0.006] and non-smoker 
group [13.59, df = 58, p = 0.001]. 
 
 
PCR and restriction enzyme analysis 
 
PCR amplification showed characteristic 179 bp band 
(Figure 1) indicating the presence of homozygous ‘MM’ 
type in all the samples. On restriction digestion, a band 
was observed at 157 bp in all the samples. As such, 
there was no ZZ mutation in these subjects in their A1AT 
gene. Since all the samples were homozygous ‘MM’ type, 
our data did not fit the ‘Hardy-Weinberg equation’. 
Sequencing of the A1AT gene also agreed to the findings 
of PCR and restriction enzyme analysis. The sequences 
obtained were aligned with the mRNA of normal (MM 
type) ATT gene as mentioned in materials and methods. 
No difference was found in position Glu 342 GAG   Lys 
AAG in COPD smoker, COPD non-Smoker, non-COPD 
smoker and non-COPD non-smoker. Details of the 
sequences for various samples are shown in sequencing 
results in Figures 2 to 5. 
 
 
DISCUSSION 
 
Amongst many risk factors of COPD, the genetic 
deficiency of A1AT attributed to ZZ type is the best 
documented reasons (Carp and Janhoff, 1978). Pheno-
type M is the normal variant, phenotypes S and Z are the 
two most frequent abnormal variants (Hutchinson et al., 
1998). Calculated values of PiZZ prevalence are  
approximately, 1:1000 to 1:45,000 in Western and 
Northern Europe, 1:45,000 to 1:10,000 in Central Europe; 
and 1: 10,000 to 1:90,000 in Eastern Europe and in 
Southernmost and Northern areas of the continent. In the 
White population of USA, Canada , New Zealand, PiZZ 
phenotype prevalence ranges from 1: 2000 to 1:7000 
individuals (Andolfatto et al., 2003) which suggests that 
the frequency of ZZ carriers are quite low in different 
parts of the world. The data of prevalence of COPD in 
Asian countries is patchy and the disease burden is high. 
Studies on COPD in the Indian population are very 
limited. There are very less data on genetic epidemiologic 
studies of AAT deficiency in countries like India; and thus 
it is essential to ascertain whether populations are at risk 
or not. Considering these aspects, the prevalence of 
COPD in a subset of Indian population was studied by us 
and presence of normal homozygous MM allele in all the 
categories individuals that were studied. The frequency of  
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Table 1. Demographic observations and lung function status of the study population. 
 
Variables 
 
 
Study population 
COPD 
smokers 
(N = 78) 
COPD 
non-smokers 
(N = 22) 
Non-COPD 
non-smokers 
(N = 38) 
Non-COPD 
smokers 
(N = 62) 
aMale 56 16 26 36 
bFemale 22 6 12 26 
Sex ratio (F/M) 0.39 0.37 0.46 0.72 
cSmoking (pack years ± S.D) 13.63 ± 5.41   5.79 ± 1.79 
dMean age (± S.D) 43.47 ± 10.49 37.59 ± 5.52 39.94 ± 5.71 34.01 ± 8.45 
eFEV1/FVC ( predicted) (± S.D) 63.75 ± 8.82 54.31 ± 11.88 94.39 ± 10.46 93.75 ±10.48 
fPost bronchodialator FEV1 (liters) 0.80 ± 0.13 0.87 ± 0.11   
 
aCOPD Smokers vs. non COPD smokers* : X2 = 2.87, p = 0.09, OR = 1.84 (0.86 - 3.96); aCOPD non Smokers vs. non COPD non smokers : 
X2 = 0.12, p = 0.72, OR = 1.23 (0.34 - 4.61); bCOPD smokers vs. non COPD smokers*: X2 = 2.87, p = 0.09, OR = 0.54 (0.25 - 1.17); bCOPD 
non smokers vs. non COPD non smokers: X2 = 0.12, p = 0.72, OR = 0.81 (0.22 – 0.98); cCOPD smokers vs. non COPD smokers* : t = 11.99, 
df = 138, p = 0.003; dCOPD smokers vs. non COPD smokers : t = 0.80, df = 138, p = 0.42; dCOPD non smokers vs. non COPD non 
Smokers: t = 1.55, df = 58, p = 0.12; eCOPD smokers vs. non COPD smokers* : t = 18.37, df = 138 , p = 0.006; eCOPD non smokers vs. non 
COPD non smokers* : t = 13.59, df = 58, p = 0.001. 
*Statistically significant. 
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Figure 1. Detection of A1AT gene by site directed mutagenesis PCR method. Lanes 1, 2 A1AT gene 179 bp normal (MM 
type). The primers used to amplify the sequence that included   the Z mutation site yielded a product of the correct size 
(179 bp) in all cases. Subsequently, PCR products were digested with Taq I enzyme. The normal fragment was 157 bp 
long. 
 
 
 
ZZ carriers of A1AT gene is rare as already documented 
(Carp and Janhoff, 1978; Hutchinson et al., 1998 and 
Andolfatto et al., 2003) and we also did not find any ZZ 
carriers in our study population. The impression that AAT 
deficiency is a rare disease has resulted into infrequent 
orders for the tests of AAT deficiency even for many 
white patients who complain of allergy, asthma or pul-
monary problems. The findings on the prevalence of AAT 
deficiency worldwide are expected to affect the diagnosis 
of people with AAT deficiency by the medical community 
(Serres et al., 2003). In this study, we found that the lung 
function was significantly declined in both COPD smokers 
(t = 18.37, df = 138, p = 0.006) and COPD non-smokers 
(t = 13.59, df = 58, p = 0.001) compared to non-COPDs. 
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GGTGCATTCATCTTGCGCCCTTGATCATCATTAAGAAGCAAAGGGTTTGTTGAACTTGACCTCGGGGGGGATAGA
CA 
TGGGTATGGCCTCTAAAAACATGGCCCCAGCAGCTTCAGTCCCTTTCTCGACGATGGTCAGCACAGCCTAAAAA 
 
 
EMBOSS_001         1 --TGCATAAGGCTGTGC-----TGACCATC-----GACGAGAAAGGG---     
35 
                       |||||....|| |||     |||.||||     ||.||.||||||    
EMBOSS_001         1 GGTGCATTCATCT-TGCGCCCTTGATCATCATTAAGAAGACAAAGGGTTT     
49 
 
EMBOSS_001        36 ACTGAAGCTG--CTGGGGCCATGTTTTTAGAGGCCATACCCATGTCTATC     
83 
                     ..||||..||  ||.|||             ||..|||..||||..|||. 
EMBOSS_001        50 GTTGAACTTGACCTCGGG-------------GGGGATAGACATGGGTATG     
86 
 
EMBOSS_001        84 CCC-------------CCCGAGGTCAAGTTCAACAAACCCTTTGTC---T    
117 
                     .||             |||.||  ||..||||           |||   | 
EMBOSS_001        87 GCCTCTAAAAACATGGCCCCAG--CAGCTTCA-----------GTCCCTT    
123 
 
EMBOSS_001       118 TCTTAATGATTGAACAAAATACCAAGTCTCCCCTCTTCATGGGAAAAGTG    
167 
                     |||..|.|||.|                        |||   |.|.||   
EMBOSS_001       124 TCTCGACGATGG------------------------TCA---GCACAG--    
144 
 
EMBOSS_001       168 GTGAATCCCACCCAAAAATAACTGCCTCTCGCTCCTCAACCCCTCCCCTC    
217 
                               ||.|||||                                 
EMBOSS_001       145 ----------CCTAAAAA--------------------------------    
152 
 
EMBOSS_001       218 CATCCCTGGCCCCCTCCCTGGATGACATTAAAGAAGGGTTGAGCTGG    264 
                                                                     
EMBOSS_001       153 -----------------------------------------------    152 
 
 
#--------------------------------------- 
#--------------------------------------- 
 
 
Figure 2. COPD smoker. 
 
 
 
Smoking itself is documented to be one of the risk factors 
for COPD and interestingly only 10 to 15% develop 
clinical symptoms of COPD (Hogg et al., 2004). 
  There was a significant association of smoking towards 
the occurrence of COPD [X2 = 6.10, p = 0.01, OR = 
2.17(1.12- 4.25)]. The COPD smokers were found to 
have higher number of pack years of smoking (t = 11.99, 
df = 138, p = 0.003); and were 2.1 times at higher risk to  
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AGTCCCCCATCACTCTTAAGTCCTTCTATCATCATTAAAAGACAAAGGGTTTGTTGAACTTGACCTCG
GGGGGGATAGACATGGGTATGGCCTCTAAAAACATGGCCCCAGCAGCTTCAGTCCCTTTCTCGACGAT
GGTCAGCACAGCCTTAAAAACGCTC 
 
 
 
EMBOSS_001         1 -------------TGCATAAGGCTGTGCTGACCATC-----GACGAGAAA     
32 
                                  | |.||||.| .|.|| |.||||     ||.||.||| 
EMBOSS_001         1 AGTCCCCCATCACT-CTTAAGTC-CTTCT-ATCATCATTAAGAAGACAAA     
47 
 
EMBOSS_001        33 GGG---ACTGAAGCTG--CTGGGGCCATGTTTTTAGAGGCCATACCCATG     
77 
                     |||   ..||||..||  ||.|||             ||..|||..|||| 
EMBOSS_001        48 GGGTTTGTTGAACTTGACCTCGGG-------------GGGGATAGACATG     
84 
 
EMBOSS_001        78 TCTATCCCCCCCGAGGTCAAGTTCAACAAA------CCCTTTGTCTTCTT    
121 
                     ..|||..||             ||.|.|||      |||.....||||   
EMBOSS_001        85 GGTATGGCC-------------TCTAAAAACATGGCCCCAGCAGCTTC--    
119 
 
EMBOSS_001       122 AATGATTGAACAAAATACCAAGTCTCCCCTCTTCATGG--GAAAAGTGGT    
169 
                                         |||   |||| ||| |.|  ||    |||| 
EMBOSS_001       120 --------------------AGT---CCCT-TTC-TCGACGA----TGGT    
140 
 
EMBOSS_001       170 GAATCCCACCC--AAAAATAACTGCCTCTCGCTCCTCAACCCCTCCCCTC    
217 
                      .|.|.||.||  |||||           |||||                 
EMBOSS_001       141 -CAGCACAGCCTTAAAAA-----------CGCTC----------------    
162 
 
EMBOSS_001       218 CATCCCTGGCCCCCTCCCTGGATGACATTAAAGAAGGGTTGAGCTGG    264 
                                                                     
EMBOSS_001       163 -----------------------------------------------    162 
 
 
Figure 3. COPD non-smoker. 
 
 
 
develop COPD. Male COPD smokers were significantly 
1.8 times at risk of developing COPD [X2 = 2.87, p = 0.09, 
OR = 1.84(0.86 – 3.96)]. Amongst female smokers with 
COPD the association of smoking was also found to be 
significant [X2 = 2.87, p = 0.09].  
In the entire study, it was found that smoking was the 
prior cause of COPD and A1AT deficiency is not 
prevalent in the population subset. In addition to this, our 
study reveals that other genes besides A1AT (ZZ type) 
could be responsible for the prevalence of COPD.  
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CCGGGATCCGGACTTCCCTCCTTGATCATCATTAAGAAGACAAAGGGTTTGTTGAACTTGACCTCGGGGGGGATA
GACATGGGTATGGCCTCTAAAAACATGGCCCCAGCAGCTTCAGTCCCTTTCTCGACGATGGTCAGCACAGCCTTA
TAAA 
 
EMBOSS_001         1 --TGCATAAGG---------CTGTGCTGACCATC-----GACGAGAAAGG     
34 
                       .|.||..||         ||    |||.||||     ||.||.||||| 
EMBOSS_001         1 CCGGGATCCGGACTTCCCTCCT----TGATCATCATTAAGAAGACAAAGG     
46 
 
EMBOSS_001        35 G---ACTGAAGCTG--CTGGGGCCATGTTTTTAGAGGCCATACCCATGTC     
79 
                     |   ..||||..||  ||.|||             ||..|||..||||.. 
EMBOSS_001        47 GTTTGTTGAACTTGACCTCGGG-------------GGGGATAGACATGGG     
83 
 
EMBOSS_001        80 TATCCCC-------------CCCGAGGTCAAGTTCAACAAACCCTTTGTC    
116 
                     |||..||             |||.||  ||..||||           ||| 
EMBOSS_001        84 TATGGCCTCTAAAAACATGGCCCCAG--CAGCTTCA-----------GTC    
120 
 
EMBOSS_001       117 ---TTCTTAATGAT--TGAACAAA-----ATACCAAGTCTCCCCTCTTCA    
156 
                        ||||..|.|||  |.|.||.|     |||  ||               
EMBOSS_001       121 CCTTTCTCGACGATGGTCAGCACAGCCTTATA--AA--------------    
154 
 
EMBOSS_001       157 TGGGAAAAGTGGTGAATCCCACCCAAAAATAACTGCCTCTCGCTCCTCAA    
206 
                                                                        
EMBOSS_001       155 --------------------------------------------------    
154 
 
EMBOSS_001       207 CCCCTCCCCTCCATCCCTGGCCCCCTCCCTGGATGACATTAAAGAAGGGT    
256 
                                                                        
EMBOSS_001       155 --------------------------------------------------    
154 
 
EMBOSS_001       257 TGAGCTGG    264 
                              
EMBOSS_001       155 --------    154 
 
 
#--------------------------------------- 
#--------------------------------------- 
 
 
Figure 4. Non-COPD smoker. 
 
 
 
Moreover, COPD is polygenic and prevalence rates are 
different in different ethnic groups. Worldwide, the ZZ 
carriers are mostly found in the Caucasians of European 
ancestry (Povey, 1990). Most of the people studied by us 
are of the tribal community belonging to Mongoloid origin 
and as such they are different from the rest of the Indian 
population. We suggest that further studies should be 
carried out to investigate individual susceptibility to 
COPD due to genetic factors or other environmental 
reasons such as air pollution, occupational exposure, etc. 
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CTCCTGTCATCTTGCGTCCTTGATCATCATTAAGAAGACAAAGGGTTTGTTGAACTTGACCTCGGGGG
GGATAGACATGGGTATGGCCTCTAAAAACATGGCCCCAGCAGCTTCAGTCCCTTTCTCGACGATGGTC
AGCACAGCCTTATAAACGGAAC 
EMBOSS_001         1 ----TG-CATAAGGCTGTGC-----TGACCATC-----GACGAGAAAGGG     
35 
                         || |||    || |||     |||.||||     ||.||.|||||| 
EMBOSS_001         1 CTCCTGTCAT----CT-TGCGTCCTTGATCATCATTAAGAAGACAAAGGG     
45 
 
EMBOSS_001        36 ---ACTGAAGCTG--CTGGGGCCATGTTTTTAGAGGCCATACCCATGTCT     
80 
                        ..||||..||  ||.|||             ||..|||..||||..| 
EMBOSS_001        46 TTTGTTGAACTTGACCTCGGG-------------GGGGATAGACATGGGT     
82 
 
EMBOSS_001        81 ATCCCC-------------CCCGAGGTCAAGTTCAACAAACCCTTT----    
113 
                     ||..||             |||.||  ||..||   ||..||||||     
EMBOSS_001        83 ATGGCCTCTAAAAACATGGCCCCAG--CAGCTT---CAGTCCCTTTCTCG    
127 
 
EMBOSS_001       114 ---------------GTCTTCTTAATGATTGAACAAAATACCAAGTCTCC    
148 
                                    |.|||.|.||.|   ||||                 
EMBOSS_001       128 ACGATGGTCAGCACAGCCTTATAAACG---GAAC----------------    
158 
 
EMBOSS_001       149 CCTCTTCATGGGAAAAGTGGTGAATCCCACCCAAAAATAACTGCCTCTCG    
198 
                                                                        
EMBOSS_001       159 --------------------------------------------------    
158 
 
EMBOSS_001       199 CTCCTCAACCCCTCCCCTCCATCCCTGGCCCCCTCCCTGGATGACATTAA    
248 
                                                                        
EMBOSS_001       159 --------------------------------------------------    
158 
 
EMBOSS_001       249 AGAAGGGTTGAGCTGG    264 
                                      
EMBOSS_001       159 ----------------    158 
#--------------------------------------- 
#--------------------------------------- 
 
 
Figure 5. Non-COPD non-smoker. 
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